Literature DB >> 4962426

Plaque reversal with MgEDTA in experimental atherosclerosis: elastin and collagen metabolism.

A Wartman, T L Lampe, D S McCann, A J Boyle.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 4962426     DOI: 10.1016/s0368-1319(67)80060-7

Source DB:  PubMed          Journal:  J Atheroscler Res        ISSN: 0368-1319


× No keyword cloud information.
  7 in total

Review 1.  Influence of nifedipine on experimental arteriosclerosis.

Authors:  A M Knorr; S Kazda
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists?

Authors:  W Schneider; G Kober; P Roebruck; H Noack; M Alle; G Cieslinski; N Reifart; M Kaltenbach
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Calcium/calmodulin-mediated action of calcitonin on lipid metabolism in rats.

Authors:  Y Nishizawa; Y Okui; M Inaba; S Okuno; K Yukioka; T Miki; Y Watanabe; H Morii
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

4.  Suppression of experimental atherosclerosis by the Ca++-antagonist lanthanum. Possible role of calcium in atherogenesis.

Authors:  D M Kramsch; A J Aspen; C S Apstein
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

5.  Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine.

Authors:  P D Henry; K I Bentley
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

Review 6.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

Review 7.  Concept of an antiatherosclerotic efficacy of calcium entry blockers. INTACT Investigators.

Authors:  S Jost; W Rafflenbeul; J Deckers; B Wiese; H Hecker; P Nikutta; P Lippolt; P Lichtlen
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.